Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.

1 , 2 Although CRC represents the second leading cause of cancer deaths worldwide, earlier detection and advances in screening and available treatments are contributing to a decreasing trend in new cases and death rates. 2 , 3 In the United States, the rate of new CRC cases decreased from 56.7 per 100 000 persons in 1992 to 34.8 in 2018, with the death rate decreasing from 23.6 to 12.8 per 100 000 persons during the same time period. 3 Biomarker profiling and the availability of target

also in 47,180 other papers

investigated baseline QoL in patients with advanced CRC in four randomized clinical trials and determined that global scores were a highly significant, independent predictor of survival. 20 These findings have been corroborated by numerous other studies concluding that patient-reported outcomes were better predictors of response than performance status. 19 In fact, improvement in physical functioning beyond baseline assessment has been associated

also in 132,142 other papers